查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2009181

大肠激躁症治疗市场规模、份额、趋势和预测：按类型、产品类型、分销管道和地区划分，2026-2034年

Irritable Bowel Syndrome Treatment Market Size, Share, Trends and Forecast by Type, Product, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

2025年全球大肠激躁症）治疗市场规模为31.1亿美元。展望未来，IMARC集团预测，该市场将在2026年至2034年间以7.5%的复合年增长率成长，到2034年达到61.2亿美元。目前，北美市场主导地位，预计2025年市占率将达到41.2%。该地区受益于完善的医疗保健基础设施、对胃肠道疾病的高度认知、先进治疗方法的广泛应用以及有利于患者获得创新疗法的有利报销政策，所有这些因素都促进了大肠激躁症治疗市场份额的增长。

由于饮食习惯改变、久坐少动的生活方式以及压力水平上升，全球大肠激躁症）的盛行率不断攀升，推动了全球对有效治疗性介入的需求。此外，老年人口的成长，尤其是老年人更容易患胃肠道疾病，也加剧了对综合治疗方案的需求。人们对肠道健康和肠脑轴的认识不断提高，促使他们主动寻求医疗保健来解决消化器官系统问题。同时，诊断技术的进步使得早期发现IBS亚型成为可能，有助于选择合适的治疗方法。个人化医疗方法的日益普及，根据患者的个别特征量身定制治疗方案，正在改善治疗效果。此外，已开发国家和开发中国家医疗保健支出的成长，也提高了IBS治疗药物的可近性。

由于多种因素，美国是治疗大肠激躁症)的关键地区。首先，美国拥有完善的医疗保健基础设施，为患者提供消化系统疾病的诊断和治疗方案。一项针对约 89,000 人的 2024 年调查发现，根据罗马 IV 标准，约 6.1% 的美国人口患有大肠激躁症。这显示该疾病的治疗需求量很大。大型製药公司对大肠激躁症新治疗方法的研发投入巨大，这是推动治疗市场成长的关键因素。此外，医师对现有治疗方法方案的了解程度也是促进新治疗方法的重要因素。透过完善的药局网路取得处方药是提高治疗方法可近性的关键因素。

人们对基于微生物组的治疗方法。

人们对调节肠道菌丛的研究兴趣日益浓厚，这正在彻底改变大肠激躁症）的治疗。研究人员正努力深入了解肠内菌丛失衡在IBS病理生理学中的作用。这种认识促成了多种独特益生菌和益生元的研发。粪便微生物移植（FMT）已被公认为治疗方法IBS的有效方法。製药业正大力投资研发旨在纠正肠内菌丛失衡的口服治疗方法。例如，2025年3月，Enterobiotics公司宣布了其新一代全光谱微生物疗法EBX-102-02的IIa期临床试验取得积极成果。该治疗方法在大肠激躁症（IBS-C）的多种症状方面显示出显着的临床疗效。我们对肠-脑相互作用认识的不断深入，也推动了IBS症状治疗方法的发展。在对肠躁症及其治疗机制有了更深入的了解之后，医疗机构和生技公司正在合作开发治疗肠躁症的独特治疗方法。

个人化医疗方法的进展

医疗保健策略向个人化方向的转变正在改变肠躁症 (IBS) 的治疗模式，医疗专业人员越来越多地根据每位患者的独特特征制定个人化的治疗方案。药物基因体学检测有助于医疗专业人员预测患者的药物治疗效果，从而优化治疗效果并同时预防药物副作用。基因谱分析和微生物组检测有助于识别对特定治疗方法高度敏感的患者群体。例如，2025 年 2 月，密西根大学医学院和克利夫兰诊所的研究人员开发了一种新型的个人化治疗方法，该方法基于血液检测结果，识别并消除大肠激躁症( IBS) 患者的诱发食物。这种以患者为中心的治疗方法越来越受欢迎，因为它有助于解决 IBS 患者症状的多样性。人工智慧演算法驱动的数位健康工具的使用正在加速治疗方法的个人化进程，从而推动大肠激躁症治疗市场的成长。

数位健康解决方案的整合

数位疗法和远端医疗工具的整合正在显着改变肠躁症（IBS）患者的治疗方式，使全球医疗保健系统的患者参与度和治疗依从性得到显着提升。用于症状和饮食管理的行动应用程式使患者能够更积极地参与自身疾病的管理。透过数位媒体提供的认知行为疗法在控制大肠激躁症症状的心理方面展现出良好的效果。此外，远端医疗工具的整合改善了大肠激躁症治疗市场的前景，尤其使居住在医疗服务匮乏地区的患者能够远端系统管理。虚拟实境（VR）工具在压力管理和以肠道为中心的催眠疗法中的应用，为管理需要多方面治疗的复杂症状患者开闢了新的途径。

按类型分析：

  • 腹泻型大肠激躁症（IBS-D）
  • 便秘型大肠激躁症（IBS-C）
  • 混合型肠躁症

腹泻型大肠激躁症（IBS-D）占据了43.5%的市场。这一细分市场的主导地位源自于大量以腹泻为主要症状的患者，以及Rifaximin和厄沙君等标靶治疗的普及。 IBS-D的慢性特征需要持续管理，因此对能够同时缓解腹痛和改善排便习惯的有效药物的需求持续存在。美国胃肠病学会于2024年10月至11月进行的一项调查显示，IBS患者平均每月因胃肠道症状而缺勤约3.6天，凸显了该疾病给患者带来的巨大负担。医护人员对该疾病认识的提高正在推动诊断率的上升和患者群体的扩大。此外，对病患教育的日益重视也鼓励患者就其持续存在的症状寻求适当的医疗照护。针对 IBS-D 症状的特定病理学机製而开发的创新治疗方法，正在改善大肠激躁症治疗市场的前景，并为患者提供更广泛的治疗选择。

产品分析：

  • Rifaximin
  • 埃尔克·萨多林
  • 鲁比普罗酮
  • Linaclotide
  • 其他的

Rifaximin以36.9%的市占率领先。Rifaximin的优点在于其作为一种非全身性抗生素的确切疗效，它能够调节肠道菌群，同时全身吸收极少，且耐受性良好。它被胃肠病学家广泛接受，并有强有力的临床证据支持，证明其在治疗腹泻型肠躁症（IBS）方面能显着改善整体症状。 2025年1月，美国食品药物管理局（FDA）核准了Rifaximin550毫克锭剂学名药的临时上市申请，显示市场对该治疗领域持续保持强劲的需求。口服给药的便利性以及症状復发后可重复疗程的特征提高了患者的接受度。利福昔明在多种胃肠道疾病Rifaximin上的不断扩展，进一步巩固了其市场地位。此外，製药公司之间的策略联盟正在增强其在不同地区的经销能力和市场渗透率，从而支持该领域的持续成长。

按分销管道分析：

  • 医院药房
  • 药局和零售药房
  • 网路商店

药局和零售药局占市场主导地位，市占率高达52.4%。这一领域的领先地位得益于零售药房网路提供的广泛覆盖和便利性，使患者能够有效地获取处方药和非处方药。遍布都市区和郊区的零售药房基础设施确保了慢性病管理中药物的持续供应。此外，零售药房从大肠激躁症（IBS）药物中获得了可观的收入，并且预计在产品供应改善的推动下，这一数字还将继续增长。药师提供的个人化咨询服务能够加深患者对治疗方案的理解，并提高用药依从性。连锁药局网路的扩张和数位化处方笺服务的整合正在简化配药流程。此外，药剂师主导的咨询计画能够引导患者改善生活方式，以辅助药物治疗，从而实现对IBS的全面管理。

区域分析：

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美在市场中占据主导地位，市占率高达41.2%。该地区的领先地位得益于大肠激躁症（IBS）的高发生率（仅在美国就有约2500万至4500万人受其影响）、完善的医疗保健基础设施和有利的保险报销体系。根据美国胃肠病学会2024年的一项调查，约81%的医疗保健专业人员认为社群媒体有助于提高大众对IBS的认知。众多主要企业投资研发创新治疗方法，进一步巩固了该地区的市场地位。先进的诊断技术能够实现精准的亚型分类，有助于选择合适的治疗方法。 Linzess和Xifaxan等处方药的高使用率显示医师对现有治疗方案充满信心。此外，政府的支持性政策和不断扩大的保险覆盖范围也使全部区域的患者更容易获得全面的胃肠道护理服务。

美国大肠激躁症治疗市场分析

美国在北美大肠激躁症(IBS) 治疗市场占据领先地位，这得益于其庞大的患者群体和先进的医疗保健体系。美国强大的製药产业持续投资于研发活动，致力于开发各种 IBS 亚型的创新治疗方法。根据美国胃肠病学会 (AGA) 于 2025 年 8 月发布的《美国 IBS 调查》，IBS 症状平均每月影响患者职场或学习效率达 11 天，凸显了该疾病给患者带来的巨大负担。由于 FDA认证核可药透过成熟的药房网络广泛供应，患者能够稳定地获得治疗选择。数位健康解决方案（例如远端医疗咨询和症状追踪应用程式）的日益普及，正在提高患者的参与度和治疗依从性。医疗保健提供者对治疗进展的认识不断提高，从而能够做出更明智的治疗方法决策。良好的报销环境支持患者在各种保险框架下获得成熟疗法和创新治疗方法。

欧洲大肠激躁症治疗市场分析

欧洲是治疗大肠激躁症)的重要市场，这得益于其完善的医疗保健体系和旨在消除胃肠道疾病污名化的宣传宣传活动。该地区拥有有利的法规结构，有利于创新治疗方法的核准和市场准入。 2025 年，AlphaSigma 公司获得欧洲药品管理局 (EMA)核准，Rifaximin新製剂专门用于治疗成人腹泻大肠激躁症 。德国、法国和英国等主要经济体的完善医疗保健基础设施为患者提供了全面的诊断和治疗服务。对病人教育的日益重视鼓励患者就持续存在的症状寻求适当的医疗照护。药物治疗、饮食疗法和行为疗法相结合的联合治疗的日益普及正在改善全部区域的治疗效果。

亚太地区大肠激躁症治疗市场分析

亚太地区大肠激躁症(IBS) 治疗市场展现出快速成长的潜力，这主要得益于主要经济体公众意识的提高、医疗基础设施的改善以及可支配收入的增加。根据一项使用 Open MetaAnalyst 进行的统计分析（该分析于 2025 年发布，回顾了 2006 年至 2024 年的研究），全球 IBS 患病率约为 14.1%，亚洲各国之间存在显着差异。印度正崛起为亚太地区的主要贡献者，这得益于诊断率的提高、饮食习惯的改变以及消费者对医疗保健参与度的增强。製药公司的增加以及创新产品的推出，正在改善全部区域获得治疗的机会。

拉丁美洲大肠激躁症治疗市场分析

在拉丁美洲，由于医疗成本上升和药物治疗可及性提高，大肠激躁症(IBS) 治疗市场正迎来不断扩大的成长机会。随着医疗专业人员将病患教育置于优先地位，该地区对胃肠道疾病的认知度也不断提高。根据 2024 年的行业报告，大型製药公司正在巴西和墨西哥扩大其分销网络，以提高治疗的可及性。医疗基础设施的改善正在加速诊断能力和治疗服务的提供。

中东和非洲大肠激躁症治疗市场分析

中东和非洲地区是大肠激躁症)治疗市场成长迅速的地区，这主要得益于医疗保健投资的增加和人们对消化器官系统疾病认识的提高。 2025 年的产业分析预测，该地区的药品分销网络将逐步扩展，医疗设施也将发展。政府旨在加强医疗服务体系的措施正在改善患者获得诊断和治疗服务的途径。跨国製药公司在该地区的业务不断拓展，也提高了主要大都市地区创新治疗方法的可及性。

竞争格局：

大肠激躁症)治疗市场呈现中等集中度的竞争格局，成熟的製药公司凭藉强大的品牌影响力、临床专长和完善的分销网络维持着市场地位。主要企业正致力于策略联盟、许可授权和研发合作，以加速创新治疗方法的开发。随着个人化医疗的日益普及，用于患者分层和治疗优化的诊断工具的投资也在增加。企业透过收购专注于消化器官系统疗法的生物技术公司来丰富产品系列。用于病人参与和远端监测的数位化健康平台的日益普及正成为新的竞争优势。产能的扩张使企业能够满足全球对成熟治疗方法日益增长的需求。此外，参与企业市场的企业正透过在新兴市场建立策略经销伙伴关係来加强其地理布局。

本报告对大肠激躁症治疗市场的竞争格局进行了全面分析，并详细介绍了所有主要企业，主要企业以下企业：

  • 雅培实验室
  • 艾尔建（艾伯维）
  • 阿尔德利克斯
  • Astellas製药公司
  • Astra Zeneca
  • 博士伦健康公司
  • GlaxoSmithKline Plc
  • 诺华公司
  • 塞维拉製药
  • 合成生物製剂
  • 武田药品工业株式会社

本报告解答的主要问题

1. 用于治疗大肠激躁症) 的药物市场规模有多大？

2.大肠激躁症）治疗市场的未来前景如何？

3. 哪些因素是推动大肠激躁症)治疗市场发展的主要因素？

4. 在大肠激躁症）治疗市场中，哪个地区占据最大的市场份额？

5. 全球大肠激躁症治疗市场的主要企业有哪些？

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球大肠激躁症治疗市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依类型

  • 腹泻型大肠激躁症（IBS-D）
  • 便秘型大肠激躁症（IBS-C）
  • 混合型肠躁症

第七章 市场区隔：依产品划分

  • Rifaximin
  • 埃尔克·萨多林
  • 鲁比普罗酮
  • Linaclotide
  • 其他的

第八章 市场区隔：依分销通路划分

  • 医院和药房
  • 药局和零售药房
  • 网路商店

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Abbott Laboratories
    • Allergan plc（AbbVie Inc.）
    • Ardelyx Inc.
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Bausch Health Companies Inc.
    • GlaxoSmithKline Plc
    • Novartis AG
    • Sebela Pharmaceuticals Inc.
    • Synthetic Biologics Inc.
    • Takeda Pharmaceutical Company Limited
Product Code: SR112026A4297

The global irritable bowel syndrome treatment market size was valued at USD 3.11 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 6.12 Billion by 2034, exhibiting a CAGR of 7.5% from 2026-2034. North America currently dominates the market, holding a market share of 41.2% in 2025. The region benefits from a well-established healthcare infrastructure, high awareness levels regarding gastrointestinal disorders, widespread adoption of advanced therapeutic options, and favorable reimbursement policies that support patient access to innovative treatments, all contributing to the irritable bowel syndrome treatment market share.

The escalating global prevalence of irritable bowel syndrome, driven by changing dietary patterns, sedentary lifestyles, and increasing stress levels among the population, is propelling the demand for effective therapeutic interventions across the globe. Furthermore, the expanding geriatric population, which demonstrates heightened susceptibility to gastrointestinal disorders, is catalyzing the need for comprehensive treatment solutions. The growing awareness regarding gut health and the gut-brain axis connection is encouraging individuals to seek medical attention for digestive issues. Additionally, advancements in diagnostic modalities are enabling earlier detection of IBS subtypes, which facilitates appropriate treatment selection. The rising adoption of personalized medicine approaches tailored to individual patient characteristics is enhancing treatment efficacy. Moreover, the expanding healthcare expenditure in both developed and developing economies is improving access to pharmaceutical interventions for IBS management.

The United States has become a key region in the treatment of irritable bowel syndrome due to a number of factors. First, the country has a good healthcare infrastructure that allows patients to access diagnostic and treatment options for gastrointestinal disorders. According to a survey conducted in 2024, involving almost 89,000 people, about 6.1% of the United States population is suffering from irritable bowel syndrome, as identified by Rome IV criteria. This shows that there is a high demand for treatment of the condition. The presence of key pharmaceutical companies that are investing in research and development of new treatment options for irritable bowel syndrome is a major factor that is propelling the growth of the treatment market. In addition, the awareness of doctors regarding the availability of treatment options is a key factor that is propelling the use of new treatment options. The availability of prescription drugs through a well-established pharmacy network is a key factor that is propelling the accessibility of treatment options.

Rising Focus on Microbiome-Based Therapies

The rising interest in researching gut microbiome modulation is revolutionizing the treatment of irritable bowel syndrome. Researchers have increasingly sought to understand the role of an imbalance in intestinal flora in the pathophysiology of IBS. This understanding has resulted in the development of unique probiotics and prebiotics. Fecal transplantation techniques have been recognized as effective treatments for IBS. The pharmaceutical industry is investing heavily in the development of oral treatments aimed at correcting imbalances in the intestinal flora. For example, in March 2025, EnteroBiotix reported positive results in phase 2a trial results for its next-generation full-spectrum microbiome treatment, EBX-102-02. This treatment demonstrated clinically significant effects in various aspects of IBS-C symptoms. Advances in understanding the interrelation between the gut and the brain have allowed for the development of treatments for IBS symptoms. This understanding of IBS and its treatment mechanisms has seen institutions and biotech companies collaborate in the development of unique treatments for IBS.

Advancement in Personalized Medicine Approaches

This shift in personalized approaches in medical strategies is altering the IBS management paradigms, with healthcare professionals increasingly personalizing treatment regimens based on individual patient characteristics. Pharmacogenomic testing helps healthcare professionals predict the outcome of medication regimens in patients, thereby optimizing therapeutic outcomes while preventing adverse reactions to drugs. Genetic profiling and microbiome testing have aided in the identification of patient groups that exhibit increased susceptibility to treatment regimens. For example, in February 2025, researchers from Michigan Medicine and Cleveland Clinic developed a new personalized approach to IBS treatment based on blood test panels to identify and remove trigger foods in patients with irritable bowel syndrome. This patient-centric approach is gaining popularity, as it helps in addressing the heterogeneity of irritable bowel syndrome manifestations in patients. The use of digital health tools, which use artificial intelligence algorithms, is helping personalize treatment regimens, thereby supporting irritable bowel syndrome treatment market growth.

Integration of Digital Health Solutions

The integration of digital therapeutics and telemedicine tools is significantly changing the way IBS patients receive treatment, making the patient engagement and adherence to treatment more effective for global healthcare systems. Mobile apps for symptom management and diet control are empowering patients to be more engaged and participatory in the management of their condition. Cognitive behavioral therapy, when conducted through digital media, has shown promising outcomes for the management of the psychological aspects of the manifestation of irritable bowel syndrome. Integration of telehealth tools has also provided the opportunity for the remote management of patients, especially for those living in underserved areas, which has improved the outlook for the irritable bowel syndrome treatment market. Integration of virtual reality tools for stress management and gut-directed hypnotherapy has provided a new avenue for the management of patients presenting with complicated forms of the condition, requiring a multimodal therapeutic approach.

Analysis by Type:

  • IBS with Diarrhea (IBS-D)
  • IBS with Constipation (IBS-C)
  • Mixed IBS

IBS with diarrhea (IBS-D) holds 43.5% of the market share. The segment dominance is attributed to the substantial patient population experiencing diarrhea-predominant symptoms and the availability of targeted therapeutic options including rifaximin and eluxadoline. The chronic nature of IBS-D necessitates ongoing management, driving sustained demand for effective medications that address both abdominal pain and altered bowel habits. According to the American Gastroenterological Association survey conducted between October and November 2024, patients with IBS reported missing approximately 3.6 work or school days per month due to gastrointestinal symptoms, highlighting the significant burden of the condition. The increasing diagnosis rates facilitated by improved awareness among healthcare providers are expanding the identified patient pool. Furthermore, the growing emphasis on patient education initiatives encourages individuals to seek appropriate medical attention for persistent symptoms. The development of innovative therapies targeting specific pathophysiological mechanisms underlying IBS-D presentations is enhancing the irritable bowel syndrome treatment market forecast, providing patients with expanded treatment alternatives.

Analysis by Product:

  • Rifaximin
  • Eluxadoline
  • Lubiprostone
  • Linaclotide
  • Others

Rifaximin leads the market with a share of 36.9%. The dominance of rifaximin is attributed to its established efficacy as a non-systemic antibiotic that modulates gut microbiota while demonstrating minimal systemic absorption and favorable tolerability profiles. The medication has gained widespread acceptance among gastroenterologists for managing diarrhea-predominant IBS symptoms, supported by robust clinical evidence demonstrating significant improvements in global IBS symptoms. According to regulatory filings in January 2025, the FDA granted tentative approval to generic versions of rifaximin 550 mg tablets, indicating continued strong market interest in this therapeutic category. The convenience of oral administration and the ability to provide repeat treatment courses for symptom recurrence have enhanced patient acceptance. The expanding indications for rifaximin across various gastrointestinal conditions are strengthening its market position. Additionally, strategic partnerships between pharmaceutical companies are enhancing distribution capabilities and market penetration across diverse geographic regions, supporting sustained segment growth.

Analysis by Distribution Channel:

  • Hospitals Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Stores

Drug stores and retail pharmacies dominate the market, with a share of 52.4%. The dominance of this segment is attributed to the widespread accessibility and convenience offered by retail pharmacy networks that enable patients to obtain prescription and over-the-counter medications efficiently. The established infrastructure of retail pharmacies across urban and suburban areas facilitates consistent medication availability for chronic condition management. Moreover, retail pharmacies generated substantial revenue from IBS treatments, with projections indicating continued expansion driven by increasing product availability. The personalized consultation services provided by pharmacists enhance patient understanding of treatment regimens and improve adherence rates. The expansion of chain pharmacy networks and the integration of digital prescription services are streamlining the medication dispensing process. Additionally, the availability of pharmacist-led counseling programs educates patients on lifestyle modifications that complement pharmacological interventions for comprehensive IBS management.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 41.2% of the share, enjoys the leading position in the market. The regional dominance is supported by the high prevalence of irritable bowel syndrome affecting approximately 25 to 45 million people in the United States alone, combined with well-established healthcare infrastructure and favorable reimbursement frameworks. According to the American Gastroenterological Association survey in 2024, approximately 81% of healthcare providers acknowledged that social media has helped increase public awareness of IBS. The presence of leading pharmaceutical companies investing in innovative therapeutic development strengthens the regional market position. Advanced diagnostic capabilities enable accurate subtype classification, facilitating appropriate treatment selection. The high adoption rates of prescription medications including Linzess and Xifaxan demonstrate strong physician confidence in available therapeutic options. Additionally, supportive government policies and expanding insurance coverage are enhancing patient access to comprehensive gastrointestinal care services across the region.

UNITED STATES IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

The United States dominates the North American irritable bowel syndrome treatment market, driven by the substantial patient population and advanced healthcare delivery systems. The country benefits from a robust pharmaceutical industry that continuously invests in research and development activities for novel therapeutic interventions targeting various IBS subtypes. According to the American Gastroenterological Association IBS in America survey released in August 2025, IBS symptoms interfere with patients' productivity at work or school for nearly 11 days per month on average, underscoring the significant disease burden. The widespread availability of FDA-approved medications through established pharmacy networks ensures consistent patient access to therapeutic options. The increasing adoption of digital health solutions including telemedicine consultations and symptom-tracking applications is enhancing patient engagement and treatment adherence. Healthcare provider awareness regarding treatment advances enables informed therapeutic decision-making. The favorable reimbursement landscape supports patient access to both established and innovative treatment options across diverse insurance frameworks.

EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

Europe represents a significant market for irritable bowel syndrome treatment, supported by established healthcare systems and increasing awareness campaigns aimed at destigmatizing gastrointestinal disorders. The region benefits from favorable regulatory frameworks that facilitate the approval and market entry of innovative therapeutic options. In 2025, Alfasigma received European Medicines Agency approval for a new formulation of rifaximin specifically indicated for treating diarrhea-predominant irritable bowel syndrome in adults. The presence of well-developed healthcare infrastructure across major economies including Germany, France, and the United Kingdom ensures comprehensive patient access to diagnostic and treatment services. Growing emphasis on patient education initiatives is encouraging individuals to seek appropriate medical attention for persistent symptoms. The expanding adoption of combination therapy approaches integrating pharmacological interventions with dietary modifications and behavioral therapies is enhancing overall treatment outcomes across the region.

ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

The Asia-Pacific region demonstrates rapid growth potential in the irritable bowel syndrome treatment market, driven by rising awareness, improving healthcare infrastructure, and increasing disposable incomes across major economies. According to statistical analysis performed using Open MetaAnalyst and published in 2025, reviewing studies from 2006 to 2024, the global prevalence of IBS is approximately 14.1%, with significant variations observed across Asian countries. India has emerged as a major contributor in Asia-Pacific, supported by increased diagnosis rates, changing dietary patterns, and growing healthcare consumer engagement. The expanding presence of pharmaceutical companies and the launch of innovative products are enhancing treatment accessibility across the region.

LATIN AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

Latin America presents growing opportunities in the irritable bowel syndrome treatment market, supported by increasing healthcare expenditure and expanding access to pharmaceutical interventions. The region is witnessing improved awareness regarding gastrointestinal disorders as healthcare providers emphasize patient education initiatives. According to industry reports in 2024, major pharmaceutical companies are expanding their distribution networks across Brazil and Mexico to enhance treatment accessibility. The developing healthcare infrastructure is facilitating improved diagnostic capabilities and treatment delivery.

MIDDLE EAST AND AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

The Middle East and Africa region represents an emerging market for irritable bowel syndrome treatment, driven by increasing healthcare investments and growing awareness regarding digestive health disorders. According to industry analysis in 2025, the region is witnessing gradual expansion in pharmaceutical distribution networks and healthcare facility development. Government initiatives aimed at strengthening healthcare delivery systems are improving patient access to diagnostic and treatment services. The expanding presence of multinational pharmaceutical companies is enhancing the availability of innovative therapeutic options across major urban centers.

Competitive Landscape:

The irritable bowel syndrome treatment market exhibits a moderately concentrated competitive landscape, with established pharmaceutical companies leveraging strong brand presence, clinical expertise, and robust distribution networks to maintain market positions. Key players are focusing on strategic partnerships, licensing agreements, and research collaborations to accelerate the development of innovative therapeutic options. The increasing emphasis on personalized medicine approaches is driving investment in diagnostic tools that facilitate patient stratification and treatment optimization. Companies are expanding their product portfolios through acquisitions of biotechnology firms specializing in gastrointestinal therapies. The growing adoption of digital health platforms for patient engagement and remote monitoring represents an emerging competitive differentiator. Manufacturing capacity expansions are enabling companies to meet rising global demand for established treatment options. Furthermore, market participants are enhancing their geographic presence through strategic distribution partnerships across emerging economies.

The report provides a comprehensive analysis of the competitive landscape in the irritable bowel syndrome treatment market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Allergan plc (AbbVie Inc.)
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • GlaxoSmithKline Plc
  • Novartis AG
  • Sebela Pharmaceuticals Inc.
  • Synthetic Biologics Inc.
  • Takeda Pharmaceutical Company Limited

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the irritable bowel syndrome treatment market?

2. What is the future outlook of the irritable bowel syndrome treatment market?

3. What are the key factors driving the irritable bowel syndrome treatment market?

4. Which region accounts for the largest irritable bowel syndrome treatment market share?

5. Which are the leading companies in the global irritable bowel syndrome treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Irritable Bowel Syndrome Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 IBS with Diarrhea (IBS-D)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 IBS with Constipation (IBS-C)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Mixed IBS
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Rifaximin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Eluxadoline
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Lubiprostone
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Linaclotide
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Allergan plc (AbbVie Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Ardelyx Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Astellas Pharma Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 AstraZeneca plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Bausch Health Companies Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 GlaxoSmithKline Plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Novartis AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sebela Pharmaceuticals Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Synthetic Biologics Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Irritable Bowel Syndrome Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 2: Global: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 3: Global: Irritable Bowel Syndrome Treatment Market: Breakup by Type (in %), 2025
  • Figure 4: Global: Irritable Bowel Syndrome Treatment Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Irritable Bowel Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Irritable Bowel Syndrome Treatment Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Irritable Bowel Syndrome Treatment (IBS with Diarrhea (IBS-D)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Irritable Bowel Syndrome Treatment (IBS with Diarrhea (IBS-D)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Irritable Bowel Syndrome Treatment (IBS with Constipation (IBS-C)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Irritable Bowel Syndrome Treatment (IBS with Constipation (IBS-C)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Irritable Bowel Syndrome Treatment (Mixed IBS) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Irritable Bowel Syndrome Treatment (Mixed IBS) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Irritable Bowel Syndrome Treatment (Rifaximin) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Irritable Bowel Syndrome Treatment (Rifaximin) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Irritable Bowel Syndrome Treatment (Eluxadoline) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Irritable Bowel Syndrome Treatment (Eluxadoline) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Irritable Bowel Syndrome Treatment (Lubiprostone) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Irritable Bowel Syndrome Treatment (Lubiprostone) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Irritable Bowel Syndrome Treatment (Linaclotide) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Irritable Bowel Syndrome Treatment (Linaclotide) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Irritable Bowel Syndrome Treatment (Other Products) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Irritable Bowel Syndrome Treatment (Other Products) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Irritable Bowel Syndrome Treatment (Hospitals Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Irritable Bowel Syndrome Treatment (Hospitals Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Irritable Bowel Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Irritable Bowel Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Irritable Bowel Syndrome Treatment (Online Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Irritable Bowel Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: North America: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: North America: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: United States: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: United States: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Canada: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Canada: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Asia-Pacific: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Asia-Pacific: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: China: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: China: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Japan: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Japan: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: India: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: India: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: South Korea: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: South Korea: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Australia: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Australia: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Indonesia: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Indonesia: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Others: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Others: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Europe: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Europe: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Germany: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Germany: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: France: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: France: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: United Kingdom: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: United Kingdom: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Italy: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Italy: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Spain: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Spain: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Russia: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Russia: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Latin America: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Latin America: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Brazil: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Brazil: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Mexico: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Mexico: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Middle East and Africa: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Middle East and Africa: Irritable Bowel Syndrome Treatment Market: Breakup by Country (in %), 2025
  • Figure 77: Middle East and Africa: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Global: Irritable Bowel Syndrome Treatment Industry: SWOT Analysis
  • Figure 79: Global: Irritable Bowel Syndrome Treatment Industry: Value Chain Analysis
  • Figure 80: Global: Irritable Bowel Syndrome Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Irritable Bowel Syndrome Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Irritable Bowel Syndrome Treatment Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Irritable Bowel Syndrome Treatment Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 4: Global: Irritable Bowel Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Irritable Bowel Syndrome Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Irritable Bowel Syndrome Treatment Market: Competitive Structure
  • Table 7: Global: Irritable Bowel Syndrome Treatment Market: Key Players